Umbralisib
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
Trial Timeline
Nov 30, 2017 → Feb 15, 2022
NCT ID
NCT03364231About Umbralisib
Umbralisib is a phase 2 stage product being developed by TG Therapeutics for Marginal Zone Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03364231. Target conditions include Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04163718 | Phase 2 | Terminated |
| NCT03364231 | Phase 2 | Completed |
| NCT02742090 | Phase 2 | Terminated |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Pirtobrutinib + Rituximab | Eli Lilly | Phase 2 | 52 |
| Epcoritamab | AbbVie | Phase 2 | 52 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 52 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 33 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| Obinutuzumab | Roche | Phase 2 | 52 |
| HMPL-689 | HUTCHMED | Phase 2 | 47 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 44 |